Who
Manher Joshi
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Rhythm Pharmaceuticals; Chief Development Officer, Soleno Therapeutics; EVP, Chief Medical Officer, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $16K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 16 Aug 2023
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | RYTM Rhythm Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 18 May 2026filed 18 May 2026 | Soleno TherapeuticsBiotechnology | SEC FORM 4 Code D | —20,171 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —72,321 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,700 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —72,321 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,700 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeutics | SEC FORM 4 Code D | —20,171 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Soleno TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,700 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code A | —4,700 at $0.00 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Soleno Therapeutics | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code M | —72,321 at $0.00 | filing |
| 10 Nov 2025filed 12 Nov 2025 | Soleno Therapeutics | SEC FORM 4 Code A | —16,071 at $0.00 | filing |
| 16 Nov 2023filed 20 Nov 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $4,79212,287 at $0.39 | filing |
| 16 Aug 2023filed 18 Aug 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $5,2833,202 at $1.65 | filing |
| 16 Aug 2023filed 18 Aug 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $6,2253,773 at $1.65 | filing |
News
No headline names them, or the companies they trade most, lately.